Positive experience of the usage of Rituximab in management of refractory myasthenia gravis in Russia

A subset of patients (15 to 20%) with myasthenia gravis (MG) remains refractory to standard types of treatment. Analysis of efficiency of rituximab, a chimeric monoclonal antibody to surface antigen of B lymphocytes (CD20), in 16 patients suffering from refractory MG was performed. In all cases, the drug was injected weekly and intravenously in the dosage of 375 mg/m2, for 4 weeks. All patients were dependent on intake of corticosteroids and cyclosporin. During rituximab therapy, the gradation of MG has significantly changed, being transformed from severe forms (IV and V MGFA class) into moderate and mild forms (III, II, and I MGFA class). Improvement of the clinical state included cease of myasthenic exacerbation, increased respiratory muscle strength; significant reduction of dosages (and even canceling) of basic pathogenetic and symptomatic treatment. Complete remission with cancellation of basic therapy was recorded in 4 (25 %) of patients within 2-year period. However, 2 of them manifested with aggravation of MG after the first course of rituximab, in 9 and 24 months, correspondingly, which required resumption of corticosteroid therapy and repeating of courses of rituximab, with positive result. In 9 (56.25 %) cases, pharmacological remission was recorded; in 3 (18.75 %) cases, there was a significant improvement of initially severe forms. In all patients rituximab therapy lead to the clinical improvement: prior to completion of the course, after the 1st and the 2nd infusion - in 12 (75 %) patients; 1 to 3 weeks after completion of the course – in 4 (25 %) patients. Maximal improvement was registered in 1 to 12 month after completion of the course of rituximab intake (at the terms of 4. ± 2.0 months). There were the following stages of basic therapy cancellation: during first 1 to 3 months of rituximab treatment, pyridostigmine and cyclosporine were cancelled; corticosteroids were dropped off gradually, according to the clinical status of patients. Increased sensitivity to steroids, even in small dosages, was recorded. Infusion reactions were dose-related and most frequently occurred during first administration of rituximab and were eliminated with slowing down of the infusion rate. Infusion reactions and side effects were absent in the course of postinfusion period in 5 (31.25 %) and 8 (50 %) patients, correspondingly.

1. Sieb J.P. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014;175(3):408–18.

2. Щербакова Н.И., Разумовский А.Ю., Митупов З.Б. и др. Особенности детской миастении с антителами к специфической мышечной тирозинкиназе. Неврологический журнал 2014;19(6):36–43. [Shcherbakova N.I., Razumovskiy A.Yu., Mitupov Z.B. et al. Peculiarities of children's myasthenia with antibodies to specific muscle tyrosine kinase. Nevrologicheskiy zhurnal = Neurological Journal 2014;19(6):36–43. (In Russ.)].

3. Burden S.J., Yumoto N., Zhang W. The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harb Perspect Biol 2013;5(5):a009167.

4. Yumoto N., Kim N.,Burden S.J. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 2012;489(7416):438–42.

5. Zhang B., Tzartos J.S., Belimezi M. et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012;69(4):445–51.

6. Кузин М.И., Гехт Б.М. Миастения. М.: Медицина, 1996. 224 с. [Kuzin M.I., Gecht B.M. Myasthenia. Moscow, Medicine, 1996. 224 p. (In Russ.)].

7. Zebardast N., Patwa H.S., Novella S.P., Goldstein J.M. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 2010;41(3):375–8.

8. Townsend M.J., Monroe J.G., Chan A.C. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010;237:264–83.

9. Lisak R.P., Ragheb S. The role of B cellactivating factor in autoimmune myasthenia gravis. Ann NY Acad Sci 2012;1274:60–7.

10. Keung B., Robeson K.R., DiCapua D.B. et al. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. J Neurol Neurosurg Psychiatry 2013;84(12):1407–9.

11. Barohn R.J., McIntire D., Herbelin L. et al. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841:769–72.

12. Bedlack R.S., Simel D.L., Bosworth H. et al. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005;64(11):1968–70.

13. Пирадов М.А., Супонева Н.А. Синдром Гийена–Барре: диагностика и лечение. М.: МЕДпресс-информ, 2011. 208 с.

14. [Piradov M.A., Suponeva N.A. Guillain–Barre Syndrome: Diagnostics and Treatment. Moscow: MEDpress-Inform, 2011. 208 p. (In Russ.)].

15. Marinos C. Dalakas. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008;10:4.

16. Mixalis L. Kosmidis, Marinos C. Dalakas. Practical considerations on the use of rituximab in autoimmune neurological diseases. Ther Adv Neurol Disord 2010; 3(2):93–105.

17. Гришина Д.А., Супонева Н.А., Пирадов М.А. Синдром Гийена–Барре: особенности восстановления демиелинизирующих и аксональных форм. Анналы клинической и экспериментальной неврологии 2012;6(4):18–25. [Grishina D.A., Suponeva N.A., Piradov M.A. Guillain–Barre Syndrome: Peculiarities of recovery from demyelination and axonal forms. Annaly klinicheskoy i experimentalnoy nevrologii = Annals of Clinical and Experimental Neurology 2012;6(4):18–25. (In Russ.)].

18. Hain B., Jordan K., Deschauer M., Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006;33(4):575–80.

19. Illa I., Diaz-Manera J., Rojas-Garcia R. et al. Sustained response to Rituximab in anti- AChR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol 2008;201– 202:90–4.

20. Burusnukul P., Brennan T.D., Cupler E.J. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis. J Clin Neuromuscul Dis 2010;12(2):85–7.

21. Lindberg C., Bokarewa M. Rituximabfor severe myasthenia gravis--experience from five patients. Acta Neurol Scand 2010;122(4);225–8.

22. Koul R., Al Futaisi A., Abdwani R. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature. Pediatr Neurol 2012;47(3):209–12.

23. Wylam M.E., Anderson P.M., Kuntz N.L., Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003;143(5):674–7.

24. Maddison P., McConville J., Farrugia M.E. et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82(6):671–3.

25. Iorio R., Damato V., Alboini P.E. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 2014 Oct 12.

26. Насонов Е.Л. Материалы совещания экспертов по регистру пациентов с ревматоидным артритом, получающих ритуксимаб (Мабтеру). Научно-практическая ревматология 2008;1. Приложение 3–10. [Nasonov E.L. Materials of consultation of experts for the register of patients with rheumatoid arthritis that receive rituximab (Mabtera). Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology 2008;1. Appendix: 3–10. (In Russ.)].